Fibroblast Differentiation into RPE Cells Using Valproic Acid

Solution Overview

Problem

Current methods for generating retinal pigment epithelial (RPE) cells from embryonic stem cells or induced pluripotent stem cells are associated with high undifferentiation potential, tumor risks, and difficulty in large-scale production, which are not suitable for commercial applications, especially in treating age-related macular degeneration.

Innovation Solution

Culturing fibroblasts in the presence of retinal pigmented epithelial (RPE)-conditioned media, with the addition of valproic acid, to induce differentiation into RPE cells, utilizing concentrated exosomes and specific growth factors, and under hypoxic conditions to enhance differentiation efficiency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If embryonic stem cells or induced pluripotent stem cells are used to generate RPE cells, then the potential for generating RPE cells exists, but the undifferentiation potential and tumor risks increase

Engineering Contradiction:

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent uses fibroblasts, which are easily obtainable, short-lived cells that do not possess the same tumorigenic potential as stem cells. These cells serve as a disposable, safe alternative for generating RPE cells without the long-term risks associated with stem cell therapy.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent employs valproic acid, a histone deacetylase inhibitor, to change the epigenetic parameters of fibroblasts, inducing their differentiation into RPE cells. This chemical parameter change allows transformation of cell fate without using problematic stem cells.

Inventive Principle:

Principle #35Parameter changes

2Ease of manufacture

If embryonic stem cells or induced pluripotent stem cells are used to generate RPE cells, then RPE cell production is possible, but large-scale production becomes difficult

Engineering Contradiction:

Core Design Contradiction:

Ease of manufactureVSProductivity

Solution Approach 1:

Fibroblasts can be easily cultured and expanded in large numbers from minimal tissue samples, enabling scalable production. They do not require complex stem cell maintenance protocols and can be produced commercially at scale.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent performs preliminary differentiation of fibroblasts into RPE cells under controlled conditions before transplantation. This preliminary action simplifies the overall manufacturing process and enables batch production of differentiated cells ready for clinical use.

Inventive Principle:

Principle #10Preliminary action

3Ease of manufacture

If conventional RPE cell sources are used, then RPE cells can be obtained, but the method is not suitable for commercial applications

Engineering Contradiction:

Core Design Contradiction:

Ease of manufactureVSProductivity

Solution Approach 1:

Fibroblasts are inexpensive to obtain from routine skin biopsies or surgical waste tissue, eliminating the need for expensive stem cell cultures. This makes the process economically viable for commercial application in treating age-related macular degeneration.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The use of valproic acid as a differentiation inducer provides a simple, scalable chemical parameter change that can be applied uniformly in commercial manufacturing settings, unlike complex stem cell differentiation protocols.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method allows for the production of differentiated RPE cells that express specific markers and possess functional capabilities, such as phagocytosis, providing a therapeutically effective solution for treating or preventing blindness and macular degeneration.

Implementation Method 1

the addition of the histone deacetylase inhibitor, valproic acid (as one example), enhances the ability of conditioned media to stimulate differentiation of fibroblasts into RPE cells

Methodology Applied

Scientific EffectHistone deacetylase inhibition:

Implementation Method 2

the culturing of fibroblasts in the presence of retinal pigmented epithelial (RPE)-conditioned media allows at least some degree of fibroblast differentiation into RPE cells

Methodology Applied

Scientific EffectCell differentiation:

Implementation Method 3

the conditioned media comprises concentrated exosomes derived from fibroblasts and/or a supernatant collected from cultured RPE cells

Methodology Applied

Scientific EffectExosome-mediated signaling:

Implementation Method 4

under hypoxic conditions to enhance differentiation efficiency

Methodology Applied

Scientific EffectHypoxia-induced differentiation:

Data Source

PatentUS20230220336A1Fibroblasts as a regenerative cellular source for the treatment of blindness

Publication Date: 2023.07.13

AI summary

Disclosed are methods and compositions useful for treatment of blindness or dry macular degeneration. In one embodiment, retinal pigmented epithelial cells are generated from fibroblasts through induction of differentiation, and/or transdifferentiation. In another embodiment, fibroblast-derived products, such as differentiated retinal pigmented epithelial cells, are provided to subjects in a therapeutically effective amount.